drozitumab human monoclonal antibody development treatment targets tumour necrosis factor related apoptosisinducing ligand trail whose receptors found surface many types malignant drozitumab developed genentech although drozitumab studied phase ii trials treating chondrosarcoma colorectal cancer nonhodgkin lymphoma nonsmall cell lung cancer development halted due lack clinical monoclonal article stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikidrozitumab